HealthAntibiotic Use Associated With IBS at Age 24 in Swedish CohortBy Naomi CalderOct 18, 2026, 10:16 PM UTC
BusinessAXIM Biotech Reaches Preliminary Agreement for Distribution of CanChew and MedChew Products Throughout South KoreaBy Nasdaq OMXApr 3, 2018, 1:02 PM UTC
BusinessMeritage Homes to Unveil Pioneering reNEWable Living Home in OrlandoBy Nasdaq OMXJan 8, 2018, 4:35 PM UTC
BusinessAxim Biotechnologies Announces Phase IIa Trial Results Validating its Proprietary Cannabinoid Delivery Method for Treatment of Irritable Bowel Syndrome (IBS)By Nasdaq OMXNov 21, 2017, 2:00 PM UTC
BusinessAXIM Biotech to Present at Rodman & Renshaw 19th Annual Global Investment Conference in New York CityBy Nasdaq OMXSep 7, 2017, 1:00 PM UTC
BusinessAXIM® Biotechnologies Secures Funding to Advance Clinical Trials and Bioequivalency StudyBy Nasdaq OMXJun 19, 2017, 1:00 PM UTC
